Share this post: 

Adult stem cells may be a novel therapeutic option for treating Scleroderma, or Systemic Sclerosis (SSc), a group of rare diseases that involve the hardening and tightening of the skin and connective tissues, which provide the framework and support for the body.


Scleroderma is a progressive auto-immune condition that has very few treatment options. It can either be localized to the skin (Morphea) or systemic with the potential of severe organ involvement, affecting blood vessels, internal organs and the digestive tract. Life expectancy in the latter group is 11 years from onset. Often, cardiac issues are the fatal event of Scleroderma

Scleroderma affects women more often than men and occurs mostly between the ages of 30 and 50. Signs and symptoms vary, depending on which parts of the body are affected. Scleroderma results from an overproduction and accumulation of collagen in body tissues. Although it’s not clear what prompts such abnormal collagen production, the body’s immune system appears to play a role.

Most traditional treatment options will only manage symptoms of Scleroderma and do not address the underlying causes of the disease. Regenerative medicine and stem cell therapy may offer new options for the affected patients.

[bctt tweet="Stem cell therapy may offer new treatment options for Scleroderma via @USStemCellInc #stemcells"]

Studies have recognized fat tissue as a source of cells with multipotency, angiogenic, reparative and immunomodulatory properties. The adipose-derived stromal vascular fraction (ADSVF) may have potential efficacy against ischaemia and skin fibrosis, two major manifestations of SSc.

In the paper, Autologous adipose-derived stromal vascular fraction in patients with systemic sclerosis: 12-month follow-up,” twelve female patients with a mean age of 54.5 years, who suffered from impaired hand function due to SSc, were assessed one year after ADSVF injection.

According to the study, the 12-month assessment showed encouraging long-term results of a single stem cell injection of ADSVF on hand disability, strength and motion; RP severity; digital ulcers (DUs); and vascular suppression score (VSS) and sclerodactyly. Some scores that were not significant at a six-month assessment became significant at 12 months, which suggests a possible continuous and progressive effect of the cell-based therapy on skin fibrosis.

The questionnaire filled out by the patients as part of the study also revealed a benefit in daily activities, housework and social activities. The results showed that no adverse events occurred between the six- and 12-month follow-ups (in hands and liposuction areas).

“The ADSVF can counterbalance various pathological mechanisms involved in hand damage, i.e. ischaemia and skin fibrosis,” the study concluded. “Due to its pleiotropic effects, ADSVF seems to be a promising therapy for the hands of Scleroderma patients.”

Stem cells are thought to be immunomodulatory and may stimulate the immune system and promote healing.  Therefore, stem cell treatment may be helpful in auto-immune conditions, which occur when a body can not recognize itself from foreign tissue and attacks itself. Stem cells may help the body re-regulate and return to a normal state. Stem cells may also help regrow and heal poor vascular systems, allowing organs to better oxygenate and function more optimally.

At U.S. Stem Cell Clinic, we utilize adult stem cells, which are found in every part of the body and can be harvested from a patient’s own tissue, such as adipose (fat) tissue, muscle, teeth, skin or bone marrow. Fat tissue is one of the most plentiful sources of stem cells in the body. In fact, approximately 500 times more stem cells can be obtained from fat than bone marrow.

During a simple and safe outpatient procedure, stem cells can easily be isolated from fat tissue in approximately 30-90 minutes under local anesthesia using a mini-lipoaspirate technique. They can then be infused or injected after the mini-liposuction. The procedure is ethical and legal, and offers minimal patient discomfort.

A new study published in the Journal of Clinical Medicine Research underscores the safety of autologous stem cell therapy in degenerative diseases and injuries. The study is the largest safety trial to date that successfully used stem cells from fat in procedures completed on 676 patients. It is also the first trial to address cells from fat in multiple diseases and with different delivery routes.

[bctt tweet="Largest safety trial of #StemCells from fat underscores the safety of autologous stem cell therapy: - @USStemCellInc"]

Our team has successfully treated over 7,000 patients with very few safety concerns reported. We are extremely encouraged by the positive patient results we are seeing from our physician-based treatments. Stem cells possess enormous regenerative potential. Our hope is that stem cell therapy will provide relief and an improved quality of life for many patients.

To find out how stem cell therapy can help you improve your life, please request your free, no-obligation consultation on our website: or by calling 954-510-3150.

Share this post: 

[contact-form-7 id=”123″ title=”contact form_split”]